The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The value of subcutaneous alnuctamab for the treatment of R/R multiple myeloma
Claudio Cerchione MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses results from the first-in-human Phase I study of subcutaneously administered alnuctamab for the treatment of relapsed/refractory (R/R) multiple myeloma (NCT03486067), and further explains the value of this agent in the myeloma treatment armamentarium. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
